Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Novartis Heart Pill Aces Major Test
by Lisa M. Jarvis
September 8, 2014
| A version of this story appeared in
Volume 92, Issue 36
Novartis’s heart-failure drug LCZ696 handily beat the standard of care, enalapril, in a large Phase III study. LCZ696, which combines the approved angiotensin II receptor antagonist valsartan with the experimental neprilysin inhibitor sacubitril, reduced the risk of cardiovascular death or hospitalization by 20% in people with systolic heart failure. On the basis of the study results, Leerink Partners stock analyst Seamus Fernandez doubled his 2026 sales forecast for the drug to $6.4 billion. Novartis plans to file for FDA approval before the end of the year.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X